ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of Traficet-EN at Digestive Disease Week Meeting; Traficet-EN Is Well-Tolerated and Appropriate for Once-Daily Oral Dosing.

CHICAGO -- ChemoCentryx, Inc. presented positive Phase 1 clinical and preclinical data from studies of the company's lead product for inflammatory bowel disease (IBD), Traficet-EN(TM) (CCX282) at the Digestive Disease Week 2005 conference being held in Chicago, Illinois May 14-19, 2005. These data indicate that Traficet-EN is highly efficacious in models of Crohn's disease and ulcerative colitis. Traficet-EN is a highly potent and selective inhibitor of the CCR9 chemokine receptor, which is specifically expressed on inflammatory cells homing to the digestive tract. In addition,…